10
Shareholders question looming patent cliff and antitrust risks in potential $400bn tie-up with Bristol Myers SquibbOriginal Article
AstraZeneca investors raise concerns over mega-merger talks
Shareholders question looming patent cliff and antitrust risks in potential $400bn tie-up with Bristol Myers SquibbOriginal Article
Africa News Matters is powered by the Colorado non-profit Africa Agenda. We credit our sources via link sharing. Support us, make a donation today!
